Home
CELNOVA PHARMA

CELNOVA PHARMA Market Share Analysis for August 2026

Industry: N/A

Domaincelnova.com

Year Founded2012

Employees51 - 200

Annual Revenue$2M - $5M

CELNOVA PHARMA

CELNOVA PHARMA (including company regionals)

celnova.com

See more website traffic and engagement information

CELNOVA PHARMA Revenue up to August 2026 is 2M - 5M

revenue generated by CELNOVA PHARMA top domains

CELNOVA PHARMA top domains revenue over 3 years

Revenue for CELNOVA PHARMA top domains

celnova.com2M - 5M

See more with Sales Intelligence

Total visits to CELNOVA PHARMA's top domains

Understand CELNOVA PHARMA market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

celnova.com1K

See more with Sales Intelligence

Avg. visit duration in CELNOVA PHARMA's top domains

Analyze CELNOVA PHARMA engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

celnova.com00:00:31

See more with Sales Intelligence

Avg. pageviews on CELNOVA PHARMA's top domains

See how CELNOVA PHARMA keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

celnova.com1.74

See more with Sales Intelligence

CELNOVA PHARMA top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by CELNOVA PHARMA

These are the website technologies, by industry, used by CELNOVA PHARMA top domains

Payment & Currencies (4)

Cart Functionality

Advertising (3)

TikTok Pixel

Social (3)

Instagram

Widget (3)

Twemoji

More Technologies

12

See all

News & Signals from CELNOVA PHARMA

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCelnova Pharma Group. partnered with Alnylam Pharmaceuticals, Inc. on Nov 4th '20.Celnova Pharma, a Latin American company focused in complex therapeutic areas, today announced the company has entered into an exclusive distribution agreement with Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, for ONPATTRO ®, a first-in-class RNAi therapeutic for the treatment of hATTR amyloidosis in adults with Stage 1 or Stage 2 polyneuropathy.

NewsCelnova Pharma Group. partnered with SpePharm Holding BV on Jan 6th '18.Celnova Pharma today announced that it has entered into an exclusive distribution agreement with SpePharm AG, a wholly owned subsidiary of Netherlands-based Norgine B.V., to commercialize DANTROLEN™ (dantrolene sodium) in the Argentine market.